Eli Lilly shares are trading higher on continued strength after the company on Thursday reported better-than-expected Q2 financial results and raised its full-year guidance. Multiple analysts raised their price targets following the report.
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly shares are trading higher following better-than-expected Q2 financial results and an increase in full-year guidance. Multiple analysts have raised their price targets for the company.
August 09, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly shares are trading higher due to strong Q2 financial results and an increase in full-year guidance. Analysts have responded positively by raising their price targets.
The strong Q2 financial results and raised full-year guidance indicate robust performance and future growth potential for Eli Lilly. The positive response from analysts, who have raised their price targets, further supports the likelihood of a short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100